Key takeaways
Rinvoq (upadacitinib) and Enbrel (etanercept) are both medications used to treat autoimmune conditions like rheumatoid arthritis (RA) and psoriatic arthritis (PsA). However, they belong to different medication classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Enbrel is a biologic disease-modifying antirheumatic drug (DMARD) that works as a monoclonal antibody. Rinvoq is taken orally, either as an extended-release tablet or an oral solution, and is typically dosed once daily. In contrast, Enbrel is administered as a subcutaneous injection, usually once a week. Both are available only as brand name products. Common side effects of Rinvoq include a higher risk of infections, acne, and nausea, whereas Enbrel may cause injection site reactions and infections. Both medications can increase the risk of serious infections and certain cancers, but Enbrel also has potential nervous system effects and can worsen heart failure. Additionally, Rinvoq should not be taken with grapefruit, while Enbrel requires proper training for injection.
